Non-alcoholic Steatohepatitis Registry Platform Study
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Terminated
Study type
Observational
Enrollment
1,122actual
Sites
16
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Following a reassessment of the company's pipeline priorities, the sponsor has elected to discontinue this project prior to its planned completion
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-22 | actual | When the study began enrolling |
| Primary completion | 2025-10-17 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-17 | actual | The whole study's end, after follow-up |
| First posted | 2023-11-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- NASH With Fibrosis
Primary outcomes
what the primary-completion date above is the date OF1.Patient demography
measured Baseline
2.The proportion of 4 NASH treatment modalities at baseline and follow-up
measured up to 3-year follow-up
3.NASH Knowledge, Belief and Practice Questionnaire responses at baseline and follow-up
measured up to 3-year follow-up
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed